Change in symptom and quality of life in COPD by Budesonide/Glycopyrronium/Formoterol fumarate pressurized metered dose inhaler (BGF pMDI) - EBISU

Study identifier:D5980R00033

ClinicalTrials.gov identifier:NCT05219630

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Change in symptom and quality of life in COPD by Budesonide/Glycopyrronium/Formoterol fumarate pressurized metered dose inhaler (BGF pMDI)

Medical condition

Pulmonary Disease, Chronic Obstructive

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Actual Enrollment

106

Study type

Observational

Age

40 Years - n/a

Date

Study Start Date: 16 May 2022
Primary Completion Date: 30 May 2023
Study Completion Date: 30 May 2023

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Apr 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria